Amylyx Pharmaceuticals garners $30m Series B

Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc., a developer of new treatments for amyotrophic lateral sclerosis, Alzheimer’s disease and other neurodegenerative diseases, has raised $30 million in Series B financing.